Outcomes after imatinib therapy
| Case no. . | Maximal tolerated daily dose of IM, mg . | IM therapy duration at last follow-up, mo . | Side effects/IM discontinuation at last follow-up . | RS before IM initiation . | RS after 2 mo of IM initiation . | cGVHD status at 2 mo of IM . | RS at last follow-up . | cGVHD response in other organs at last follow-up* . | cGVHD status at last follow-up . | Percentage CS reduction (last dosage mg/d) . | Overall follow-up, mo . | Follow-up since IM initiation, mo . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1† | 600 | 74.1+ | None/no | 10 | 3 | PR | 0 | Joints contracture | CR | 100% (0) | 147.2 | 74.1 | Alive |
| 2 | 400 | 14.0+ | Diarrhea/no | 22 | 4 | PR | 0 | Mouth, eyes | CR | 100% (0) | 133.1 | 14.0 | Alive |
| 3 | 400 | 5.8 | Cough/yes | 12 | 3 | PR | 3 | Bronchiolitis, joints contracture | PR | 100% (0) | 41.5 | 11.7 | Alive |
| 4 | 400 | 10.6 | Nausea, diarrhea, lumbar bone pain/yes | 8 | 2 | PR | 1 | Mouth | PR (>90%) | 100% (0) | 55.4 | 12.8 | Alive |
| 5 | 400 | 2.1 | Rash/yes | 12 | 12 | Failure | NE | — | failure | NE | 65.4 | 14.5 | Alive |
| 6 | 400 | 0.5 | Paresthesia, muscle cramps, diarrhea/yes | 10 | NE | NE | NE | — | failure | NE | 95.5 | 11.7 | Alive |
| 7 | 400 | 3 | Muscle cramps, diarrhea/yes | 8 | 4 | MR | 6 | Mouth | Relapse | NE | 25.1 | 8.9 | Alive |
| 8 | 400 | 2.1 | Headache, muscle cramps/yes | 21 | 13 | MR | 21 | Mouth, eyes, bronchiolitis, joints contractures | Relapse | NE | 46.8 | 13.8 | Died of infection |
| 9 | 400 | 2.0 | Edema, muscle cramps, diarrhea/yes | 11 | 9 | MR | 9 | Mouth, joints contracture | Relapse | NE | 51.5 | 11.4 | Alive |
| 10 | 400 | 1.5 | Muscle cramps/yes | 11 | 7 | MR | 7 | Mouth, liver | Relapse | NE | 33.4 | 9.5 | Alive |
| 11 | 400 | 11.4+ | None/no | 30 | 9 | PR | 6 | Mouth | PR (>90%) | 100% (0) | 56.6 | 11.4 | Alive |
| 12 | 100 | 4.1+ | None/no | 0‡ | 0 | PR | 0 | Joints contracture | PR (>90%) | 100% (0) | 66.3 | 4.1 | Alive |
| 13 | 400 | 6.0+ | Edema/no | 19 | 15 | PR | 9 | Eyes, joints contracture | PR | 100% (0) | 30.1 | 6.0 | Alive |
| 14 | 300 | 4.5+ | Nausea, vomiting, diarrhea/no | 12 | 11 | MR | 10 | Eyes, joints contractures | MR | 0 (30) | 67.2 | 4.5 | Alive |
| Case no. . | Maximal tolerated daily dose of IM, mg . | IM therapy duration at last follow-up, mo . | Side effects/IM discontinuation at last follow-up . | RS before IM initiation . | RS after 2 mo of IM initiation . | cGVHD status at 2 mo of IM . | RS at last follow-up . | cGVHD response in other organs at last follow-up* . | cGVHD status at last follow-up . | Percentage CS reduction (last dosage mg/d) . | Overall follow-up, mo . | Follow-up since IM initiation, mo . | Status at last follow-up . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1† | 600 | 74.1+ | None/no | 10 | 3 | PR | 0 | Joints contracture | CR | 100% (0) | 147.2 | 74.1 | Alive |
| 2 | 400 | 14.0+ | Diarrhea/no | 22 | 4 | PR | 0 | Mouth, eyes | CR | 100% (0) | 133.1 | 14.0 | Alive |
| 3 | 400 | 5.8 | Cough/yes | 12 | 3 | PR | 3 | Bronchiolitis, joints contracture | PR | 100% (0) | 41.5 | 11.7 | Alive |
| 4 | 400 | 10.6 | Nausea, diarrhea, lumbar bone pain/yes | 8 | 2 | PR | 1 | Mouth | PR (>90%) | 100% (0) | 55.4 | 12.8 | Alive |
| 5 | 400 | 2.1 | Rash/yes | 12 | 12 | Failure | NE | — | failure | NE | 65.4 | 14.5 | Alive |
| 6 | 400 | 0.5 | Paresthesia, muscle cramps, diarrhea/yes | 10 | NE | NE | NE | — | failure | NE | 95.5 | 11.7 | Alive |
| 7 | 400 | 3 | Muscle cramps, diarrhea/yes | 8 | 4 | MR | 6 | Mouth | Relapse | NE | 25.1 | 8.9 | Alive |
| 8 | 400 | 2.1 | Headache, muscle cramps/yes | 21 | 13 | MR | 21 | Mouth, eyes, bronchiolitis, joints contractures | Relapse | NE | 46.8 | 13.8 | Died of infection |
| 9 | 400 | 2.0 | Edema, muscle cramps, diarrhea/yes | 11 | 9 | MR | 9 | Mouth, joints contracture | Relapse | NE | 51.5 | 11.4 | Alive |
| 10 | 400 | 1.5 | Muscle cramps/yes | 11 | 7 | MR | 7 | Mouth, liver | Relapse | NE | 33.4 | 9.5 | Alive |
| 11 | 400 | 11.4+ | None/no | 30 | 9 | PR | 6 | Mouth | PR (>90%) | 100% (0) | 56.6 | 11.4 | Alive |
| 12 | 100 | 4.1+ | None/no | 0‡ | 0 | PR | 0 | Joints contracture | PR (>90%) | 100% (0) | 66.3 | 4.1 | Alive |
| 13 | 400 | 6.0+ | Edema/no | 19 | 15 | PR | 9 | Eyes, joints contracture | PR | 100% (0) | 30.1 | 6.0 | Alive |
| 14 | 300 | 4.5+ | Nausea, vomiting, diarrhea/no | 12 | 11 | MR | 10 | Eyes, joints contractures | MR | 0 (30) | 67.2 | 4.5 | Alive |
IM indicates imatinib; RS, Rodman score; cGVHD, chronic graft-versus-host disease; CS, corticosteroids; PR, partial response; CR, complete response; NE, not evaluable; and MR, minor response.
Only patients showing at least PR are mentioned.
Patient 1 had simultaneous disease recurrence (CML) at time of IM initiation.
Patient 12 did not have assessable sclerotic skin lesions.